FDA approves dabrafenib plus trametinib and liquid formulations to treat BRAF V600E low-grade glioma
Pediatric patients with BRAF V600E low-grade glioma as young as 1 year can now be treated with dabrafenib plus trametinib following its FDA approval.
Poll reveals how parents determine risks, punishments, and likelihood of vaping in their children
A recent survey from the C.S. Mott Children’s Hospital National Poll on Children’s Health revealed how addictive parents believe vaping is for children.
Zolgensma yields 100% bulbar function response in presymptomatic SMA
All children included in the analysis achieved swallowing, oral nutrition, and airway protection outcomes.
Catching a common cold gives children COVID-19 immunity
Exposure to a common seasonal coronavirus stimulates a memory T cell response that protects children against COVID-19. However, this immune response peaks at age 6.
Pediatric speech disorder diagnoses more than doubled amid COVID-19 pandemic
Recent data revealed a 110% increase in speech disorder diagnoses for children aged 0 to 12 years in 2022, compared to the pre-pandemic era.
Earlier HPV vaccination associated with completed vaccine series
In a recent review, children with vaccination against human papillomavirus (HPV) initialized at a younger age were more likely to receive their full vaccination series.
The impact of mild sleep deprivation on the quality of life in children
As little as 39 minutes less sleep per night for 1 week can have an impact on the quality of life of children.
Butyrate effective for treating pediatric obesity
In a recent study, reductions in body mass index along with further beneficial effects were found when using oral butyrate supplementation for treating pediatric obesity.
Which drug products are abused by adolescents?
At the 44th National Association of Pediatric Nurse Practitioners Conference, drug products abused by teenagers were discussed.
Treating pediatric atopic dermatitis
At the 44th National Association of Pediatric Nurse Practitioners Conference, methods of treating atopic dermatitis were discussed.
Managing aggression in pediatric patients
At the 44th National Association of Pediatric Nurse Practitioners Conference, pediatric aggression was discussed, including which patients are at greater risk and which management strategies are most appropriate.
Choosing the right oral contraceptive
At the 44th National Association of Pediatric Nurse Practitioners Conference, guidelines for prescribing oral contraceptives were discussed.
Managing pregnancy in adolescents
At the 44th National Association of Pediatric Nurse Practitioners Conference, evidence-based approaches for supporting pregnant adolescents were discussed.
Highlighting pediatric nurse practitioners
Jessica Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN, pediatric nurse practitioner, discusses the vital role of nurse practitioners and key takeaways from the 44th National Association of Pediatric Nurse Practitioners Conference.
How to manage viral infections in pediatric patients
At the 44th National Association of Pediatric Nurse Practitioners Conference, data was presented on the effectiveness of vaccines and antivirals in preventing life threatening conditions.
CDC immunization schedule updates
At the 44th National Association of Pediatric Nurse Practitioners Conference, the CDC provided an updated immunization schedule, detailing new changes.
Managing disordered eating in adolescents with type 1 diabetes
At the 44th National Association of Pediatric Nurse Practitioners Conference, a session presented data explaining why teenagers with type 1 diabetes were at high risk for developing anorexia and bulimia.
Diagnosing and treating PCOS in adolescents
At the 44th National Association of Pediatric Nurse Practitioners Conference, data was presented on how to diagnose and treat polycystic ovarian syndrome in adolescent patients.
SDX/d-MPH safe and effective against pediatric ADHD
In a recent study, positive safety and efficacy outcomes for serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH; Azstarys; KemPharm) were found in children aged 6 years and older with attention-deficit/hyperactivity disorder (ADHD).
CASSY tool effective in predicting adolescent suicide attempts
In a recent study, the Ask Suicide-Screening Questions (ASQ) and the Computerized Adaptive Screen for Suicidal Youth (CASSY) tools both showed predictive viability for suicide attempts in adolescents.
FDA approves trofinetide for treatment of Rett syndrome
The FDA has approved trofinetide (Daybue; Acadia Pharmaceuticals) for treating Rett syndrome in patients aged 2 years and older.
Pediatric COVID-19 symptoms differed by variant
The Omicron variant caused the most symptoms in pediatric patients. However, there were no differences in adverse outcomes by COVID-19 variant.
COVID-19 vaccine effective against hospitalization from Omicron variant
In a recent study, children aged 5 to 11 years were less likely to be hospitalized with the Omicron strand if they received vaccination against COVID-19.
Penicillin allergy documentation uninformative in allergy tabs
In a recent study, penicillin allergy documentation was uninformative in allergy tabs, and children were not often referred to allergists.
Covis withdraws Makena from the market
Covis, the manufacturer of the controversial preterm birth prevention drug Makena, has announced it will voluntarily withdraw the drug from the market after recommendations from the Center for Drug Evaluation and Research.
E-cigarette use more common among sexual minority youth
In a recent study, the prevalence of e-cigarette use was greater among sexual minority youth than heterosexual or questioning youth.
Poor rate of outpatient care following mental health ED visit
In a recent study, a poor connection was reported between mental health emergency department discharge and follow-ups through outpatient care.
FDA accepts sNDA for empagliflozin in children with type 2 diabetes
A supplemental New Drug Application for empagliflozin (Jardiance; Boehringer Ingelheim and Eli Lilly and Company) in pediatric patients with type 2 diabetes has been accepted by the FDA.
Childhood respiratory infection linked to adult mortality
In a recent study, the risk of death from respiratory diseases during adulthood almost doubled in individuals who experienced a lower respiratory tract infection at a young age.
FDA accepts NDA for berdazimer gel to treat molluscum contagiosum
Following positive results from a phase 3 clinical trial, the FDA has accepted a New Drug Application for berdazimer gel, 10.3% (Novan) for treating patients with molluscum contagiosum.